{"id":75777,"date":"2026-08-21T12:22:26","date_gmt":"2026-08-21T04:22:26","guid":{"rendered":"https:\/\/flcube.com\/?p=75777"},"modified":"2026-08-21T12:22:27","modified_gmt":"2026-08-21T04:22:27","slug":"cstones-cs5007-ind-approved-by-nmpa-advancing-egfr-her3-bispecific-adc-for-egfr-resistant-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75777","title":{"rendered":"CStone&#8217;s CS5007 IND Approved by NMPA, Advancing EGFR\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CStone Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2616:HKG\">HKG: 2616<\/a>) announced that the <strong>Investigational New Drug (IND) application<\/strong> for <strong>CS5007<\/strong> has been approved by China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>, clearing the way for clinical evaluation of the company&#8217;s EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC).<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Investigational New Drug (IND) \u2014 approved<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>CS5007 (EGFR\/HER3 bispecific ADC)<\/td><\/tr><tr><td><strong>Sponsor<\/strong><\/td><td>CStone Pharmaceuticals (HKG: 2616)<\/td><\/tr><tr><td><strong>Global Phase 1 Launch<\/strong><\/td><td>Initiated in Australia, June 2026; first patient enrolled<\/td><\/tr><tr><td><strong>Planned Enrollment<\/strong><\/td><td>~310 patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>CS5007<\/strong>, a <strong>bispecific antibody\u2011drug conjugate (ADC)<\/strong><\/li>\n\n\n\n<li><strong>Dual Targeting:<\/strong> Designed to simultaneously target both <strong>EGFR<\/strong> and <strong>HER3<\/strong> signaling pathways<\/li>\n\n\n\n<li><strong>Resistance Rationale:<\/strong> Expected to overcome <strong>acquired resistance to EGFR\u2011targeted therapies<\/strong>, a major unmet need as tumors on EGFR inhibitors inevitably progress<\/li>\n\n\n\n<li><strong>Therapeutic Window:<\/strong> Engineered to deliver antitumor activity with a <strong>favorable safety profile<\/strong>, a key differentiator in the increasingly crowded ADC field<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-global-phase-1-study\" class=\"wp-block-heading\">Clinical Development \u2013 Global Phase 1 Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Type<\/strong><\/td><td>Global, multicenter Phase 1<\/td><\/tr><tr><td><strong>Start<\/strong><\/td><td>June 2026, Australia \u2014 first patient successfully enrolled<\/td><\/tr><tr><td><strong>China Participation<\/strong><\/td><td>To be conducted in parallel following NMPA IND approval<\/td><\/tr><tr><td><strong>Target Enrollment<\/strong><\/td><td>Approximately 310 patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The China IND approval enables <strong>CS5007<\/strong> to join the ongoing global study, supporting a synchronized development strategy across key markets.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Momentum:<\/strong> <strong>CS5007<\/strong> rides the industry&#8217;s hottest modality, with bispecific ADCs representing the next frontier beyond first\u2011generation single\u2011target conjugates<\/li>\n\n\n\n<li><strong>Resistance Opportunity:<\/strong> Positioning against acquired resistance to EGFR\u2011targeted therapies addresses one of oncology&#8217;s most persistent clinical challenges, with broad applicability across EGFR\u2011driven cancers such as non\u2011small cell lung cancer<\/li>\n\n\n\n<li><strong>Dual\u2011Pathway Logic:<\/strong> Simultaneous EGFR and HER3 targeting may blunt compensatory escape routes tumors use to evade single\u2011pathway blockade, potentially translating into deeper and more durable responses<\/li>\n\n\n\n<li><strong>Pipeline Context:<\/strong> For <strong>CStone<\/strong>, the IND clearance adds a differentiated ADC asset to its immuno\u2011oncology franchise, complementing its existing portfolio of checkpoint inhibitors and targeted agents<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding CS5007&#8217;s regulatory progress, clinical development, and commercial potential for CStone Pharmaceuticals. Actual results may differ due to risks including clinical outcomes, enrollment dynamics, competitive pressures in the ADC space, and regulatory requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082100002_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082100002_c.\"><\/object><a id=\"wp-block-file--media-057a4c50-1929-4321-8a63-9a229bf70a88\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082100002_c.pdf\">2026082100002_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082100002_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-057a4c50-1929-4321-8a63-9a229bf70a88\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CStone Pharmaceuticals (HKG: 2616) announced that the Investigational New Drug (IND) application for CS5007 has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,62,188,856],"class_list":["post-75777","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-cstone-pharmaceuticals","tag-hkg-2616"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CStone&#039;s CS5007 IND Approved by NMPA, Advancing EGFR\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CStone Pharmaceuticals (HKG: 2616) announced that the Investigational New Drug (IND) application for CS5007 has been approved by China&#039;s National Medical Products Administration (NMPA), clearing the way for clinical evaluation of the company&#039;s EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75777\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CStone&#039;s CS5007 IND Approved by NMPA, Advancing EGFR\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors\" \/>\n<meta property=\"og:description\" content=\"CStone Pharmaceuticals (HKG: 2616) announced that the Investigational New Drug (IND) application for CS5007 has been approved by China&#039;s National Medical Products Administration (NMPA), clearing the way for clinical evaluation of the company&#039;s EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75777\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-21T04:22:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-21T04:22:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75777#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75777\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CStone&#8217;s CS5007 IND Approved by NMPA, Advancing EGFR\\\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors\",\"datePublished\":\"2026-08-21T04:22:26+00:00\",\"dateModified\":\"2026-08-21T04:22:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75777\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"CStone Pharmaceuticals\",\"HKG: 2616\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75777#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75777\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75777\",\"name\":\"CStone's CS5007 IND Approved by NMPA, Advancing EGFR\\\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-21T04:22:26+00:00\",\"dateModified\":\"2026-08-21T04:22:27+00:00\",\"description\":\"CStone Pharmaceuticals (HKG: 2616) announced that the Investigational New Drug (IND) application for CS5007 has been approved by China's National Medical Products Administration (NMPA), clearing the way for clinical evaluation of the company's EGFR\\\/HER3 bispecific antibody\u2011drug conjugate (ADC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75777#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75777\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75777#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CStone&#8217;s CS5007 IND Approved by NMPA, Advancing EGFR\\\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CStone's CS5007 IND Approved by NMPA, Advancing EGFR\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"CStone Pharmaceuticals (HKG: 2616) announced that the Investigational New Drug (IND) application for CS5007 has been approved by China's National Medical Products Administration (NMPA), clearing the way for clinical evaluation of the company's EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75777","og_locale":"en_US","og_type":"article","og_title":"CStone's CS5007 IND Approved by NMPA, Advancing EGFR\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors","og_description":"CStone Pharmaceuticals (HKG: 2616) announced that the Investigational New Drug (IND) application for CS5007 has been approved by China's National Medical Products Administration (NMPA), clearing the way for clinical evaluation of the company's EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC).","og_url":"https:\/\/flcube.com\/?p=75777","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-21T04:22:26+00:00","article_modified_time":"2026-08-21T04:22:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75777#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75777"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CStone&#8217;s CS5007 IND Approved by NMPA, Advancing EGFR\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors","datePublished":"2026-08-21T04:22:26+00:00","dateModified":"2026-08-21T04:22:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75777"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","CStone Pharmaceuticals","HKG: 2616"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75777#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75777","url":"https:\/\/flcube.com\/?p=75777","name":"CStone's CS5007 IND Approved by NMPA, Advancing EGFR\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-21T04:22:26+00:00","dateModified":"2026-08-21T04:22:27+00:00","description":"CStone Pharmaceuticals (HKG: 2616) announced that the Investigational New Drug (IND) application for CS5007 has been approved by China's National Medical Products Administration (NMPA), clearing the way for clinical evaluation of the company's EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75777#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75777"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75777#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CStone&#8217;s CS5007 IND Approved by NMPA, Advancing EGFR\/HER3 Bispecific ADC for EGFR\u2011Resistant Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75777"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75777\/revisions"}],"predecessor-version":[{"id":75779,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75777\/revisions\/75779"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}